Everything below concerns synaptic plasticity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
For Canadian domestic consumption of non-CRFPCP pork, ractopamine hydrochloride is permitted to be sold over the counter with applications in meal or pellet feed for finishing barrows and gilts (up to 10 mg/kg for last six weeks), confined finishing cattle (up to 30 mg/kg for last 42 days), and finishing heavy turkeys (up to 9 mg/kg for 14 days). The withdrawal period was set to 0 days.
=== 14 May === Russian missiles struck Ternopil Oblast, causing damage to civilian property. The Russian military claimed to have launched strikes on deployment points of Ukrainian forces and arms depots in the oblast as well as in Petropavlivka in Dnipropetrovsk Oblast. The Governor of Russia's Bryansk Oblast said a Ukrainian drone attack damaged a food processing facility in Starodub. The Russian Ministry of Defence confirmed the death of Colonels Vyacheslav Makarov and Yevgeny Brovko of the 4th Motorized Rifle Brigade during fighting in Bakhmut. The Russian military said it had repelled Ukrainian attacks in the north and south of Bakhmut while Yevgeny Prigozhin, head of the Wagner Group said his forces had advanced up to 130 metres (430 ft) over the past 24 hours. He also claimed control over 28 multi-story buildings in western districts of Bakhmut and estimated Ukrainian forces were still holding 20 buildings and a total area of 1.69 square km (0.65 square miles). Meanwhile, the Ukrainian Defence Ministry said its forces captured more than ten enemy positions in the north and south of Bakhmut and cleared a large area of forest near Ivanivske. The Washington Post, citing leaked documents from the Pentagon, reported that Prigozhin secretly contacted Ukrainian intelligence in January 2023 to reveal Russian military positions in exchange for a Ukrainian withdrawal from Bakhmut, which was refused, and advised them to advance towards Crimea while informing them of shortages in Russian ammunition.
== Definitions == Translational research is aimed at solving particular problems; the term has been used most commonly in life sciences and biotechnology, but applies across the spectrum of science and humanities. In the field of education, it is defined for school-based education by the Education Futures Collaboration (www.meshguides.org) as research which translates concepts to classroom practice. Examples of translational research are commonly found in education subject association journals and in the MESHGuides which have been designed for this purpose. In bioscience, translational research is a term often used interchangeably with translational medicine or translational science or bench to bedside. The adjective "translational" refers to the "translation" (the term derives from the Latin for "carrying over") of basic scientific findings in a laboratory setting into potential treatments for disease. Biomedical translational research adopts a scientific investigation/enquiry into a given problem facing medical/health practices: it aims to "translate" findings in fundamental research into practice. In the field of biomedicine, it is often called "translational medicine", defined by the European Society for Translational Medicine (EUSTM) as "an interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside and community", from laboratory experiments through clinical trials, to therapies, to point-of-care patient applications.
=== Brand names === Trimipramine is marketed throughout the world mainly under the brand name Surmontil. Other notable brand names of trimipramine have included Herphonal, Rhotrimine, Sapilent, Stangyl, and Tydamine.
=== Pharmacodynamics === Equilin is an estrogen, or an agonist of the estrogen receptors (ERs), the ERα and ERβ. In terms of relative binding affinity for the ERs, equilin has about 13% and 49% of that of estradiol for the ERα and ERβ, respectively. Analogously to the reversible transformation of estrone into estradiol by 17β-hydroxysteroid dehydrogenase, equilin can be converted into the more potent estrogen 17β-dihydroequilin in the body. This estrogen has about 113% and 108% of the relative binding affinities of estradiol for the ERα and ERβ, respectively. Equilin is present in CEEs in the form of equilin sulfate, which itself is inactive and acts as a prodrug of equilin via steroid sulfatase. Similarly to synthetic estrogens like ethinylestradiol, equilin and CEEs have disproportionate effects in certain tissues such as the liver and uterus relative to bioidentical human estrogens like estradiol and estrone. Because of their disproportionate potency in the liver, equilin and CEEs have relatively increased effects on liver protein synthesis compared to estradiol. A dosage of 0.25 mg/day equilin sulfate is equivalent to 0.625 mg/day CEEs in terms of relief from hot flashes. At a dosage of 0.625 mg/day equilin sulfate, the increases in circulating levels of sex hormone-binding globulin (SHBG), corticosteroid-binding globulin, and angiotensinogen were 1.5 to 8 times those observed with estrone sulfate.
Sources: en.wikipedia.org
The former Trump Plaza hotel in Atlantic City, New Jersey is demolished in a controlled implosion. The U.S. Food and Drug Administration approves the Patient Specific Talus Spacer 3D-printed talus implant for humanitarian use. The Patient Specific Talus Spacer is the first in the world and first-of-its-kind implant to replace the talus—the bone in the ankle joint. February 18 – NASA successfully lands its Perseverance rover on Mars, seven months after launching. February 19 – The U.S. officially rejoins the Paris Agreement, 107 days after leaving. February 22 New York Rangers winger Artemi Panarin takes a personal leave of absence after the Russian tabloid Komsomolskaya Pravda publishes a story in which former Kontinental Hockey League coach Andrei Nazarov accuses him of sexually assaulting an 18-year old Latvian woman in Riga. The team releases a statement calling the allegations against Panarin an "intimidation tactic" against him after speaking out against "recent political events", most notably expressing his support for Russian opposition leader Alexei Navalny, who was detained upon return to Russia from Germany. Enabling legislation for New Jersey Public Question 1 is signed into law by governor Phil Murphy, making New Jersey the 14th state to legalize recreational cannabis. The Supreme Court rejects a last-ditch attempt by Donald Trump to shield his financial records, and issues an order requiring his accountants to turn over his tax and other records to prosecutors in New York.
=== Normal–phase chromatography === Normal–phase chromatography was one of the first kinds of HPLC that chemists developed, but has decreased in use over the last decades. Also known as normal-phase HPLC (NP-HPLC), this method separates analytes based on their affinity for a polar stationary surface such as silica; hence it is based on analyte ability to engage in polar interactions (such as hydrogen-bonding or dipole-dipole type of interactions) with the sorbent surface. NP-HPLC uses a non-polar, non-aqueous mobile phase (e.g., chloroform), and works effectively for separating analytes readily soluble in non-polar solvents. The analyte associates with and is retained by the polar stationary phase. Adsorption strengths increase with increased analyte polarity. The interaction strength depends not only on the functional groups present in the structure of the analyte molecule, but also on steric factors. The effect of steric hindrance on interaction strength allows this method to resolve (separate) structural isomers. The use of more polar solvents in the mobile phase will decrease the retention time of analytes, whereas more hydrophobic solvents tend to induce slower elution (increased retention times). Very polar solvents such as traces of water in the mobile phase tend to adsorb to the solid surface of the stationary phase forming a stationary bound (water) layer which is considered to play an active role in retention.
== N-Glycosidic bonds in DNA == DNA molecules contain 5-membered carbon rings called deoxyriboses that are directly attached to two phosphate groups and a nucleobase that contains amino groups. The nitrogen atoms from the amino group in the nucleotides are covalently linked to the anomeric carbon of the ribose sugar structure through an N-glycosidic bond. Occasionally, the nucleobases attached to the ribose undergo deamination, alkylation, or oxidation which results in cytotoxic lesions along the DNA backbone. These modifications severely threaten the cohesiveness of the DNA molecule, leading to the development of diseases such as cancer. DNA glycosylases are enzymes that catalyze the hydrolysis the N-glycosidic bond to free the damaged or modified nucleobase from the DNA, by cleaving the carbon-nitrogen glycosidic bond at the 2' carbon, subsequently initiating the base excision repair (BER) pathway. Monofunctional glycosylases catalyze the hydrolysis of the N-glycosidic bond via either a stepwise, SN1 like mechanism, or a concerted, SN2 like mechanism. The stepwise function, the nucleobase acts as a leaving group before the anomeric carbon gets attacked by the water molecule, producing a short-lived unstable oxacarbenium ion intermediate. This intermediate rapidly reacts with the nearby water molecule to substitute the N-glycosidic bond of the ribose and the nucleobase with an O-glycosidic bond with a hydroxy group. The concerted mechanism, the water acts as a nucleophile and attacks at the anomeric carbon before the nucelobase gets to act like a leaving group.
George Walker Bush was born on July 6, 1946, at Grace-New Haven Hospital in New Haven, Connecticut. He is the first child of George Herbert Walker Bush and Barbara Pierce, and was raised in Midland and Houston, Texas. His five siblings are Robin, Jeb, Neil, Marvin and Dorothy. Robin died from leukemia at the age of three in 1953. His paternal grandfather, Prescott Bush, was a U.S. senator from Connecticut. His father was Ronald Reagan's vice president from 1981 to 1989 and the 41st president of the United States from 1989 to 1993. Bush has distant English and German ancestry, along with more distant (over seven generations removed) Dutch, Welsh, Irish, French, and Scottish roots. Bush attended public schools in Midland, Texas, until the family moved to Houston after he had completed seventh grade. He then spent two years at The Kinkaid School, a college-preparatory school in Piney Point Village, Texas. Bush later attended Phillips Academy, a boarding school in Andover, Massachusetts, where he played baseball and was the head cheerleader during his senior year. He attended Yale University from 1964 to 1968, graduating with a Bachelor of Arts degree in history. During this time, he was a cheerleader and a member of the Delta Kappa Epsilon, serving as the president of the fraternity during his senior year. Bush became a member of the Skull and Bones society as a senior. Bush was a rugby union player and was on Yale's 1st XV. He characterized himself as an average student.
== Research == The minimum dose (5 mg/kg) was confirmed in a clinical trial performed by HTI Bio-services, Inc. It evaluated the effective dose for the treatment of an infected dermal wound. The study included forty-eight mixed breed dogs (both male and female) with weights ranging from 14.5-24.5 kilograms. These dogs were randomly placed into treatment groups. Once wounds were created, the dogs were inoculated with culture both containing both Escherichia coli and Klebsiella pneumoniae. Pertinent observations and measurements were then taken and tabulated. Culture scores were significantly reduced, confirming 5 mg/kg to be an effective dose. Clinical field trials were also performed to evaluate both the efficacy and safety of difloxacin tablets. Clinical signs of bacterial infections were defined in a protocol. Dogs who presented to investigators with these signs were admitted into the study. In total, eighteen veterinarians located in four different geographical areas of the U.S. (Southeast, Midwest, Northwest, and West) conducted these clinical efficacy and safety evaluations.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.